0000950170-23-017958.txt : 20230504 0000950170-23-017958.hdr.sgml : 20230504 20230504170032 ACCESSION NUMBER: 0000950170-23-017958 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230428 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20230504 DATE AS OF CHANGE: 20230504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tracon Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001394319 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 342037594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36818 FILM NUMBER: 23889791 BUSINESS ADDRESS: STREET 1: 4350 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 800 CITY: San Diego STATE: CA ZIP: 92122 BUSINESS PHONE: 858-550-0780 MAIL ADDRESS: STREET 1: 4350 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 800 CITY: San Diego STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Tracon Pharmaceuticals Inc DATE OF NAME CHANGE: 20070324 8-K 1 tcon-20230428.htm 8-K 8-K
false000139431900013943192023-04-282023-04-28

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2023

 

 

Tracon Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36818

34-2037594

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4350 La Jolla Village Drive, Suite 800

 

San Diego, California

 

92122

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 550-0780

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

TCON

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 1.02 Termination of a Material Definitive Agreement.

On April 28, 2023, the loan and security agreement, dated as of September 2, 2022 and amended as of December 22, 2022, March 31, 2023 and April 15, 2023 (the “RGC Loan Agreement”), by and among TRACON Pharmaceuticals, Inc. (the “Company”), each party to the RGC Loan Agreement from time to time a borrower thereunder, the lenders from time to time a party thereto and Runway Growth Finance Corp., as administrative agent and collateral agent for the lenders (“Lender”), terminated automatically in accordance with its terms. The Company continues to be bound by certain terms under the RGC Loan Agreement that customarily survive the termination of similar agreements, including, without limitation, certain indemnification and confidentiality obligations.



The RGC Loan Agreement provided, among other things, that (i) on or before April 28, 2023, if the Company has raised at least $25.0 million in net cash proceeds from certain equity or debt transactions prior to making such request, Lender may, in its sole and absolute discretion, allow or deny loaning to the Company an aggregate principal amount of $10.0 million, with the full amount funded in a single disbursement and (ii) if the loan described in clause (i) above was not made by April 28, 2023, the maturity date would be April 28, 2023, the RGC Loan Agreement would terminate on that date, and the Company would not be obligated to pay the prepayment fee described in the RGC Loan Agreement but the final payment fee described in the RGC Loan Agreement would become immediately due and payable. The Company did not request the loan described in clause (i) above and the RGC Loan Agreement terminated. As of April 28, 2023, the Company had no amounts due or owed under the RGC Loan Agreement for any borrowed amounts; however, the Company is still obligated to pay final payment fee described in the RGC Loan Agreement of $425,000.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TRACON Pharmaceuticals, Inc.

 

 

 

 

Date:

May 4, 2023

By:

/s/ Charles P. Theuer, M.D., Ph.D.

 

 

 

Charles P. Theuer, M.D., Ph.D.
President and Chief Executive Officer

 

 EX-101.SCH 2 tcon-20230428.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 tcon-20230428_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 tcon-20230428_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Apr. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 28, 2023
Entity Registrant Name Tracon Pharmaceuticals, Inc.
Entity Central Index Key 0001394319
Entity Emerging Growth Company false
Securities Act File Number 001-36818
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 34-2037594
Entity Address, Address Line One 4350 La Jolla Village Drive, Suite 800
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (858)
Local Phone Number 550-0780
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TCON
Security Exchange Name NASDAQ
XML 6 tcon-20230428_htm.xml IDEA: XBRL DOCUMENT 0001394319 2023-04-28 2023-04-28 false 0001394319 8-K 2023-04-28 Tracon Pharmaceuticals, Inc. DE 001-36818 34-2037594 4350 La Jolla Village Drive, Suite 800 San Diego CA 92122 (858) 550-0780 false false false false Common Stock, par value $0.001 per share TCON NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tcon-20230428.htm tcon-20230428.xsd tcon-20230428_lab.xml tcon-20230428_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tcon-20230428.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tcon-20230428.htm" ] }, "labelLink": { "local": [ "tcon-20230428_lab.xml" ] }, "presentationLink": { "local": [ "tcon-20230428_pre.xml" ] }, "schema": { "local": [ "tcon-20230428.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tcon", "nsuri": "http://www.traconpharma.com/20230428", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tcon-20230428.htm", "contextRef": "C_12779c2a-8033-4151-a707-7a70188e34b1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tcon-20230428.htm", "contextRef": "C_12779c2a-8033-4151-a707-7a70188e34b1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-017958-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-017958-xbrl.zip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end